Study 10 of 10Orforglipron (LY-3502970) literatureJAMATop journal2026
Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial.
Not reported in abstract.
Where it sits
this study against the rest of the orforglipron (ly-3502970) corpus2
Preclinical · this one
3
Observational
0
Open-label
2
Randomised
3
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Orforglipron (LY-3502970) corpus
AMetabolic and Glycemic Effects of Orforglipron, a GLP-1 Receptor Agonist, in Adults With or Without Diabetes: A Network Meta-Analysis of Randomised Clinical Trials.Endocrinology, diabetes & metabolism · 2023 · n=4878 · MD: -12.13 kg at 36 weeks, n=4878, p<0.001 for 45 mg vs placebo.HumanBOrforglipron, a Small-Molecule Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA), Has Neuroprotective and Anti-Inflammatory Effects.Cells · 2026 · Brain/plasma and CSF/plasma ratios: 0.0078.In vitroAEfficacy and Safety of Oral GLP-1 RA Orforglipron on Weight and Glycemic Control According to Diabetes Status: A Systematic Review and Meta-Analysis.Diabetes technology & therapeutics · 2026 · n=6140 · -1.29% HbA1c, n=6140.HumanBOral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison.Diabetes, obesity & metabolism · 2023 · -3.2%-points (95% CI: -5.9, -0.4; treatment-regimen estimand)HumanAOrforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trial.Contemporary clinical trials communications · 2026 · n=712 · Not reported in abstract.HumanBPatient preferences for pharmacological treatments for obesity: The VOICE study.Obesity pillars · 2026 · n=351 · RAI: 62.7% for mode/frequency of administration.Human